Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Ana Rita LeiteAntónio Angélico-GonçalvesFrancisco Vasques-NóvoaMarta Borges-CanhaAdelino F Leite-MoreiraJoão Sérgio NevesJoao Pedro FerreiraPublished in: Diabetes, obesity & metabolism (2022)
Our aim was to study the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on the risk of any cardiovascular event in adults with overweight or obesity and without diabetes. We conducted a random-effects meta-analysis of placebo-controlled randomized controlled trials. Nine trials were eligible and, in total, 11 430 patients were included, of which 7702 (67%) were submitted to treatment with GLP-1 RA. During follow-up, 673 participants receiving GLP-1 RA treatment (8.7%) and 416 participants receiving placebo (11.2%) had a cardiovascular event. Treatment with GLP-1 RA versus placebo resulted in a reduction in the risk of any cardiovascular event (RR = 0.81, CI 0.70-0.92; p = .001). In overweight or obese adults without diabetes, treatment with GLP-1 RA reduced the risk of cardiovascular events. Our findings support the use of GLP-1 RA for reducing the cardiovascular risk of these patients.
Keyphrases
- cardiovascular events
- type diabetes
- rheumatoid arthritis
- weight loss
- cardiovascular disease
- end stage renal disease
- metabolic syndrome
- placebo controlled
- chronic kidney disease
- double blind
- disease activity
- adipose tissue
- ankylosing spondylitis
- weight gain
- bariatric surgery
- clinical trial
- insulin resistance
- systematic review
- prognostic factors
- combination therapy
- peritoneal dialysis
- glycemic control
- obese patients
- idiopathic pulmonary fibrosis
- phase ii
- neural network